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Abstract
Osteopontin (OPN), also known as SPP1 (secreted phosphoprotein), is an integrin binding glyco-phosphoprotein
produced by a variety of tissues. In cancer patients expression of OPN has been associated with poor prognosis in
several tumor types including breast, lung, and colorectal cancers. Despite wide expression in tumor cells and
stroma, there is limited evidence supporting role of OPN in tumor progression and metastasis. Using phage display
technology we identified a high affinity anti-OPN monoclonal antibody (hereafter AOM1). The binding site for
AOM1 was identified as SVVYGLRSKS sequence which is immediately adjacent to the RGD motif and also spans the
thrombin cleavage site of the human OPN. AOM1 efficiently inhibited OPNa binding to recombinant integrin avb3
with an IC50 of 65 nM. Due to its unique binding site, AOM1 is capable of inhibiting OPN cleavage by thrombin
which has been shown to produce an OPN fragment that is biologically more active than the full length OPN.
Screening of human cell lines identified tumor cells with increased expression of OPN receptors (avb3 and
CD44v6) such as mesothelioma, hepatocellular carcinoma, breast, and non-small cell lung adenocarcinoma (NSCLC).
CD44v6 and avb3 were also found to be highly enriched in the monocyte, but not lymphocyte, subset of human
peripheral blood mononuclear cells (hPBMCs). In vitro, OPNa induced migration of both tumor and hPBMCs in a
transwell migration assay. AOM1 significantly blocked cell migration further validating its specificity for the ligand.
OPN was found to be enriched in mouse plasma in a number of pre-clinical tumor model of non-small cell lung
cancers. To assess the role of OPN in tumor growth and metastasis and to evaluate a potential therapeutic
indication for AOM1, we employed a Kras
G12D-LSLp53
fl/fl subcutaneously implanted in vivo model of NSCLC which
possesses a high capacity to metastasize into the lung. Our data indicated that treatment of tumor bearing mice
with AOM1 as a single agent or in combination with Carboplatin significantly inhibited growth of large metastatic
tumors in the lung further supporting a role for OPN in tumor metastasis and progression.
Introduction
OPN is a multifunctional protein involved in several
pathological processes such as inflammation and cancer
[1]. As an acidic glycophosphoprotein, OPN contains a
RGD (arginine-glycine-aspartate) integrin binding motif,
a hydrophobic leader sequence (indicative of its secre-
tory characteristic), a thrombin cleavage site adjacent to
RGD domain, and a cell attachment sequence [2]. OPN
has been found to be present in three forms in tissues
and fluids: i) an intracellular protein in complex with
hyaluronan-CD44-ERM (ezrin/radixin/moesin) that is
involved in migration of tumor and stromal cells [3]; ii)
an extracellular protein that is abundant at mineralized
tissues [4]; iii) a secreted protein that is found in fluids
isolated from metastatic tumors [5] and also found in
organs such as placenta [6,7], breast [8], and testes [9].
At the protein synthesis level, OPN undergoes extensive
post-translational modification including phosphoryla-
tion and glycosylation [10]. Additionally, there are three
splice variants of OPN (OPNa, OPNb, and OPNc) that
may have distinct characteristics in different tissues and
tumor types [11]. For example, OPN-c has been sug-
gested to be expressed in invasive breast tumors and is
highly correlated with patient’s survival in HER-2 breast
patients [12]. Irrespective of OPN isoform, a series of
other studies have suggested a role for plasma OPN as a
biomarker of tumor progression in colon [13,14], lung
[15], and prostate cancers [16,17].
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to CD44-ERM and several integrins including aVb1,
avb3, and aVb5 [18]. Given the wide expression of
integrins and CD44, both cancer cells as well as stromal
compartment are targeted by OPN in the tumor mass.
Binding of OPN to the above receptors on tumor cells
triggers downstream signaling pathways including Ras,
Akt, MAPK, Src, FAK and NF-KB [1] that collectively
lead to the following in tumor cells: i) invasion to ECM
(extracellular matrix) mainly via upregulation of MMPs
[19] (matrix metalloproteinases) and uPAs [20] (uroki-
nase plasminogen activator) by OPN; ii) increased
migration and adhesion of tumor cells [21]; iii) inhibi-
tion of cell death likely through upregulation of anti-
apoptosis mediators such as GAS6 [22]; and iv) develop-
ment of pre-metastatic niche [23]. Additionally, tumor
stroma such as endothelial cells [18] and immune infil-
trating cells [24,25] (particularly monocytes) express
OPN receptors. Angiogenesis is proven to be a critical
component of tumor mass by supplying oxygen and
nutrients for cancer cells [26]. Angiogenesis in the
tumor is induced by OPN directly by binding to avb3,
and/or indirectly via upregulation of VEGF (vascular
endothelial growth factor) [27,28]. Additionally, OPN
may suppress immune response via inhibition of iNOS
(inducible nitric oxide synthase) in immune infiltrating
cells further creating a conducive microenvironment for
growth and invasion of tumor cells [29,30]. It is note-
worthy to mention that cleavage by thrombin enhances
biological activity of OPN [31] through increased expo-
sure of N-terminal domain to integrin binding sites [32]
and/or via formation of a complex between the c-term-
inal domain and cyclophilline and CD147 resulting in
the activation of Akt1-2 and MMP-2 [33]. VEGF may
accelerate thrombin activity to generate cleaved-OPN
that in turn results in increased migration of endothelial
cells [34].
To further understand the role of OPN in tumor pro-
gression, we screened phage display libraries and identi-
fied a monoclonal anti-OPN antibody (AOM1) capable
of neutralizing human and mouse OPN. In vitro, AOM1
inhibited OPN-induced migration of tumor cells and
monocytes. Furthermore, AOM1, as a single agent or in
combination with a cytotoxic agent, inhibited growth of
large tumors in the lung in a metastatic model of
NSCLC indicating a role for OPN in lung metastasis.
Materials and methods
Inhibition of thrombin mediated degradation of human
OPN
Ability of AOM1 to inhibit OPN cleavage by thrombin
was evaluated in a western blot assay. Reaction buffer
included PBS pH 7.2 containing 2 mM MgCl2 and 0.2
mM MnCl2. Both AOM1 and the control antibodies
were added to human OPN (2.2 μg/ml) and reaction
buffer to a total volume of 900 μl. Anti-OPN antibody
concentration was titrated from 3 nM to 1000 nM.
OPN and AOM1 were pre-incubated at 37°C on a
rotary shaker for 1 hour to allow association to occur.
Next, 100 ul of 50% thrombin-agarose slurry (in reaction
buffer, Sigma, CA) was added to the reaction mixture
and were incubated for 2 hours at 37°C on a rotary sha-
ker. Reaction mixture supernatant was removed and
analyzed by SDS-PAGE and western blot using a mouse
anti-human OPN antibody (34E3, IBL, Japan) specific to
the N-terminal fragment of thrombin cleaved OPN.
Intensity of the western blot staining of the thrombin
cleaved N-terminal fragment was compared at different
concentrations of AOM1 to approximate an IC50 for
thrombin cleavage inhibition.
Integrin binding inhibition assay
Immunosorbent plates (COSTAR Corning, CA) were
coated with 100 μl/well integrin aVb3( 1 0μg/ml, R&D
System, MN) in Buffer 1 (PBS 7.2 with 0.2 mM MnCl2
and 2 mM MgCl2) for overnight at 4°C. Plates were
then washed three times with Buffer 1 and non-specific
binding sites blocked with 200 μl/well of blocking buffer
(3% BSA in Buffer 1) for two hours at 37°C. Next, plates
were washed three times with Buffer 1 and 100 μlo f
OPN/test antibody mixture was applied to the plate sur-
face. The OPN/test antibody mixture was prepared as
follows. Human OPN (R&D systems, MN) was main-
tained at a constant final concentration (6 μg/ml) in the
blocking buffer. OPN was mixed with either AOM1 or
control antibody. Antibody concentrations were titrated
from 10 μM in a three-fold dilution series to approxi-
mately 0.1 nM. Human OPN and test antibody were
pre-incubated for 1 hour at room temperature on a
rotary mixer before being applied to the aVb3c o a t e d
ELISA plates. After a washing step (3 times with Buffer
1 + 0.05% Tween-20 and three times with Buffer 1
alone), rabbit polyclonal anti-human OPN antibody (O-
17, IBL, Japan) was added to the plates (100 μl/well) at
a concentration of 4 μg/ml for 1 hour at room tempera-
ture. Plates were then washed (3 times with Buffer 1 +
0.05% Tween-20 and 3 times with Buffer 1 alone) and
goat-anti-rabbit antibody (Fc specific) HRP conjugate
(Jackson Immunoresearch, PA) was added to each well
(100 μl/well, 1 in 5000 dilution in Block Buffer) for 1
hour at room temperature. Following final washes (3
times with Buffer 1 + 0.05% Tween-20 and 3 times with
Buffer 1 alone) ELISA was developed with 100 μl/well
BM Blue POD substrate (Roche, NJ) and the colori-
metric reaction was stopped with 100 ul/well 0.2 M
H2SO4. Absorbance at 450 nm was measured using a
Spectromax plate reader (Molecular Devices, CA) and
analysis was conducted using Microsoft Excel Data-
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moidal saturation binding model.
Selectivity of AOM1 for OPN
EIA/RIA plates (Corning, NY) were coated with 1 mg/
ml of RGD-motif containing protein which included
OPN, Thrombospondin, Vitronectin, ColIAI or Fibro-
nectin (R&D Systems, MN) in Buffer 1 (PBS pH 7.2
containing 2 mM MgClR2R and 0.2 mM MnClR2R for
16 hours at 4°C). Plates were washed three times with
Buffer 1 and were blocked with commercially available
Blocking buffer (3% BSA (Rockland, PA) in Buffer 1) fol-
lowed by washing three times with Buffer 1 and AOM1
was added at 0, 0.1, 1, 10, and 1000 nM in blocking buf-
fer, and incubated at RT for 1 hr. Plates were washed (3
times with Buffer 1 + 0.05% Tween-20 and three times
with Buffer 1 alone). Goat Anti-Human IgG (Fc) Peroxi-
dase Conjugate (Jackson Immunoresearch, PA) was
added (1 in 5000 in block buffer) and plates were incu-
bated at RT for 1 h followed by a wash (3 times with
Buffer 1 + 0.05% Tween-20 and three times with Buffer
1 alone). BM Blue Solution (Roche, NJ) was used to
develop the assay and quenched with 0.18 M
HR2RSOR4R. Absorbance at 450 nm was detected using
a Spectramax plate reader (Molecular Devices, CA) and
data were analyzed using Microsoft Excel.
Characterization of AOM1 Fab binding to OPN
Binding of Fab fragment of AOM1 to recombinant OPN
was determined using surface plasmon resonance (SPR)
analysis on a Biacore 3000 instrument (GE Healthcare,
CA). Recombinant OPNs (human: 1433-OP-050/CF;
mouse 441-OP-050/CF; R&D System, MN) was immobi-
lized on a CM5 biosensor chip using standard EDC/
NHS amine coupling chemistry, at 25°C using a 1 μM
in 10 mM sodium acetate pH 5.0. Experiments were
carried out in a buffer containing 10 mM HEPES pH
7.4, 150 mM NaCl, 0.005% P20 at 25°C using a two-fold
dilution series of the Fab. Data were analyzed using the
Scrubber2 software (BioLogic Software, Pty., Australia).
Injections were referenced t oab l a n ks u r f a c ea n db ya
buffer blank. Kinetic characteristics were obtained from
a fit to a simple kinetic binding model using the Scrub-
ber2 program software (BioLogic Software, Pty.,
Australia).
Epitope mapping
Epitope mapping studies were carried out using an over-
lapping series of synthetic peptides (CPC Scientific, CA)
designed based on the primary sequence of OPN. Pep-
tides corresponding to the region 143-172 of human
OPN are listed below:
1. 143EVFTPVVPTVDTYDGRGDSVVYGLRSKSKK172
2. 143EVFTPVVPTVDTYDGRGDSVVYGLR167
3. 143EVFTPVVPTVDTYD156
4. 156DGRGDSVVYGLRSKSKK172
Binding of each peptide was determined to the immo-
bilized anti-OPN antibody by SPR. The antibody was
immobilized on a CM5 chip by standard EDC/NHS
amine coupling chemistry, at 25°C using a 1 μMi n1 0
mM sodium acetate pH 5.0. Peptides were diluted to 5
uM in 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005%
P20 and diluted with a two-fold series. The samples
were analyzed at a flow rate of 20 uL/min and were
injected serially over all four flow cells for a 5 minute
association and a 5 minute dissociation. The binding
data were fit to a simple equilibrium binding model
using Scrubber2 (BioLogic Software, Pty., Australia).
Migration assay was performed in transwell plates
(VWR, CA) using standard protocol provided by the
manufacturer. All the cell lines (JHH4, MSTO-211H
and MDA-MB435) were purchased from ATCC (Ameri-
can Type Culture Collection; VA) and were grown in
RPMI (GIBCO BRL, CA) supplemented with 10% FBS
(Sigma Aldrich, CA). Cells were harvested from flasks
and were placed (5 × 10^4 Cells in 100 ul plain media)
on the top chamber of transwells. Plates were incubated
in a cellular incubator for 4 hrs and migrating cells were
counted in the bottom well.
To measure migrating hPBMCs, blood samples were
taken from healthy individuals under guidelines provided
by Pfizer Department of Environmental Health and
Safety. Nearly 40 ml blood was collected from a healthy
individual in a 4 CPT tube and was span 20 min at 3000
RPM followed by harvesting PBMCs in 50 ml polypropy-
lene tubes, washing twice in plain RPMI1640 and starva-
tion for 2 hrs at 37°C. Cells were then spiked with AOM1
or control antibody and were incubated at 37°C for 1 hr
in a cell incubator. Next, 150 ul of pretreated PBMC in
RPMI was added to the top chamber of transwell while
bottom wells contained either plain RPMI with or with-
out OPN (R&D System, MN, 5 ug/ml). Plates were incu-
bated in a cell incubator for 4 hrs at 37°C and migratory
cells were counted in the bottom well.
Flowcytometry, histology and ELISA
Cells (tumor cells or PBMCs) were stained with anti-
CD44v6-APC (R&D System, MN) or anti-avb3-PE
(R&D System, MN) antibodies using standard protocol
provided by the manufacturer. Mouse antibodies (CD44-
FITC av-APC and b3-PE) were all purchased from BD
Biosciences. All the stained samples were analyzed in a
Calibur instrument (BD Biosciences, CA) and data were
analyzed in FCS express software (De Novo, CA).
Whole lungs were collected from treated animals and
were preserved in formalin and embedded in paraffin.
Sections of lungs were stained with Hematoxylene and
Eosin staining (H&E) to evaluate efficacy of different
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ples were collected when mice were euthanized at the
end of in vivo s t u d ya n dm o u s eO P Nw a sm e a s u r e db y
an ELISA kit (R&D System, MN) using a protocol pro-
vided by the manufacturer.
Tumor implantation
Kras
G12D-LSLp53
fl/fl mice (n = 10) were inhaled intrana-
sally with Adeno-CMV-Cre (2.5 × 10^7 viral particles,
University of Iowa, IO). Using trocar catheter, pieces of
tumors were removed from the lungs at 16 weeks post-
inhalation and were immediately implanted subcuta-
neously in Scid/beige mice. Tumor bearing mice (n =
10) were randomized at 8 days post-implantation when
tumors reached 200 mm
3 using caliper measurement
[35]. Randomized animals were treated with vehicle,
Carboplatin (25 mg/kg weekly, Hospira, IL), AOM1 (30
mg/kg weekly) and combination of both compounds
using intra-peritoneal route of administration. The
entire study was terminated when vehicle-treated
tumors reached ~2500 mm
3. Whole lungs were fixed in
formalin, embedded in paraffin and were cut using a
microtome machine in the laboratory. Slides from each
treatment were stained in H&E (hetoxylin and eosin)
and metastasis in each section was assessed by a certi-
fied pathologist. Lung lesions were quantified based on
size of tumors to small (less than 10 cells) medium (10-
200) and large (more than 200 cells).
Results
Development and characterization of AOM1 monoclonal
antibody targeting mouse and human OPN
Analysis of aa (amino-acid) sequences of three different
isoforms of OPN (a, b and c) provided some clue about
common regions between the isotypes in order to iden-
tify antibodies potentially capable of binding and neutra-
lizing all forms of OPN (Figure 1A). Consistent with a
published report [36], there is a conserved aa sequence
in all three isoforms corresponding to binding sites for a
series of integrins including a4b1, a4b7, a9b1, a9b4,
avb3, avb1, avb5, avb5, a5b1 and a8b1 making it an
attractive epitope to target with an anti-OPN neutraliz-
ing antibody. Screening of phage display libraries identi-
fied several antibodies with the potential to bind to the
integrin biding sequence of OPN. Further detailed bio-
chemical and cellular characterization led to the discov-
ery of AOM1, a fully human monoclonal antibody with
the ability of neutralizing both human and mouse OPN.
Species specificity of AOM1 was determined by SPR
(surface plasmon resonance) using OPN immobilized on
a Biacore chip. AOM1 was found to cross-react with
human and mouse OPN (Figure 1.B). Using a Fab frag-
ment of AOM1, affinity of AOM1 to human OPNa was
measured to be 50 nM. Epitope recognized by AOM1
on human OPN was determined using a series of over-
lapping synthetic peptides corresponding to the region
143-172 of human OPN. AOM1 binds to SVVYGLRSKS
motif which is a binding site for integrins a4b1, a4b7,
a9b1,a n da9b4R (Figure 1). The epitope is immediately
adjacent to the RGD sequence which is the binding site
for another family of integrins (avb3, avb1, avb5, avb5,
a5b1 and a8b1). In addition, the AOM1 binding epitope
spans over the main thrombin cleavage site on OPN.
The ability of AOM1 to inhibit OPN binding to integrin
avb3 which is considered to be the major receptor by
which OPN regulates cancer cell migration and prolif-
eration, and to prevent thrombin-mediated cleavage of
OPN was characterized in an ELISA-based and western
blot assays, respectively. In both cases AOM1 demon-
strated high inhibitory activity (Figure 1B&C). Therefore,
this unique binding epitope allows AOM1 to inhibit
multiple functional activities of OPN by preventing sig-
naling through integrins as well as blocking cleavage of
OPN by thrombin which has been shown to produce
functionally more active OPN fragments than the full
length molecule. Of note, AOM1 has high selectivity for
OPN and does not recognize other RGD containing pro-
teins which is consistent with its binding epitope.
OPN acts as a chemotactic agent for human tumor cells
and monocytes
To identify a potential therapeutic indication for AOM1
we first screened a series of human and mouse cancer
cells to identify cell lines that express OPN receptors in
particular avb3 and CD44v6. As illustrated in Figure
2A-C, FACS analysis identified at least three cell lines
expressing OPN receptors including JHH4, MDA-
MB435, and MSTO-211H. Furthermore, transwell assay
data showed that these cells were capable of migrating
to OPN (5 μg/ml) indicating a functional relevance for
receptor expression in these cells (Figure 2D-F). Treat-
ment with AOM1 (150 μg/ml) fully inhibited cell migra-
tion suggesting that blockade of integrin binding site is
sufficient to inhibit cell migration to OPN.
In addition to tumor cells, we investigated expression
of OPN receptors in human PBMCs (peripheral blood
mononuclear cells; Figure 3A). Flowcytometry data indi-
cated expression of avb3a n dt oal e s s e re x t e n tC D 4 4 v 6
in the entire human PBMCs (Figure 3B). Further gating
on populations of granulocytes and monocytes (GM) vs.
lymphocytes showed a greater expression of both recep-
tors in GM compared to lymphocyte subset (Figure 3C).
The migration assay supported flowcytometry data since
only GM, but not lymphocytes, migrated towards OPN
(Figure 3D). Overall, and consistent with published
reports [37], we have provided receptor expression and
functional data further supporting a role for OPN in
tumor growth via affecting both cancer cells and stroma.
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In addition to human cells we also analyzed mouse cell
lines to identify a preclinical model to test efficacy of
AOM1 with specific focus on lung tumors. OPN has
been shown to be highly enriched in lung tumors [38].
Surgical removal of primary lung tumors in patients
results in a significant reduction in levels of OPN in
plasma further indicating a role for OPN as a biomarker
of tumor progression in NSCLC [39]. Consistent with
these findings, a mass spectrometry method was devel-
oped to quantify three different isoforms of OPN (a, b,
and c) in plasma samples obtained from NSCLC
patients and healthy individuals. Analysis of plasma
samples showed that all three isoforms of OPN were
present in healthy individuals but were less abundant
than in cancer patients. Of note, elevated OPNa
accounted for the majority of the increased total OPN
in cancer patients [40].
The Kras
G12D-LSLp53
fl/fl GEMM (genetically engi-
neered mouse model) represents one of the most rele-
vant models of human NSCLC [41]. Biology of tumor
progression and efficacy of therapeutic agents have been
extensively studied in this model. Intranasal inhalation
of viral particles containing Cre-recombinase results in
activation of mutated KrasP
G12DP and ablation of p53
that in turn lead to tumor formation and progression in
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Figure 1 Development of anti-OPN antibody. A Amino acid sequence of OPNa (full length OPN). Truncated isoforms OPNb and OPNc are
highlighted with blue and yellow, respectively. Binding sites for integrins are highlighted with green (RGD binding integrins) and orange (LDV
binding integrins). Thrombin cleavage site is marked by a red arrow. B Characterization of AOM1 including its cross-reactivity, binding epitope,
dissociation constant (KD) for the Fab and its ability to inhibit binding of recombinant OPNa to immobilized integrin avb3 have been
determined. C Selectivity of AOM1 for human OPN over other RGD-motif containing proteins was assessed by ELISA as detailed in Materials and
Methods. RGD containing proteins were immobilized on an immunosorbent plate and binding of AOM1 assessed at 0.1, 1, 10 and 1000 nM
concentrations. With the exception of 1000 nM AOM1 vs. ColA1, there was no binding observed at any concentration of AOM1 up to 1000 nM
versus thrombospondin, vitronectin, ColA1 and fibronectin whilst saturated binding was observed vs. OPN at antibody concentrations as low as
0.1 nM AOM1. Each bar represents mean OD450 nm value of triplicate measurements with standard error bars.
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patients with a similar mutation [42]. Therefore, the
availability of these mice prompted us to test efficacy of
AOM1 on tumor growth and progression. However,
repeat-dose treatment of these immuno-competent mice
with AOM1, a fully human IgG2, resulted in rapid
clearance of the antibody from plasma possibly due to
the development of anti-drug antibodies (no changes in
AOM1 clearance was observed following repeated treat-
ment of immune-compromised mice, data not shown).
To circumvent this limitation, we modified this tumor
model by de novo isolating tumors from the lung of
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Figure 2 OPN act as a chemotactic factor in human cells lines expressing OPN receptors. A-C Using flowcytometry expression of OPN
receptor, mainly CD44v6 and avb3 was assessed in series of human cell lines. Three cell types found to have greater expression of one or both
receptors. These lines include JHH4 hepatocellular (A) carcinoma, MSTO211H mesothelioma (B) and MDA-MB435 melanoma cells (C). D-F
Migration assay provided functional relevance for expression of OPN receptors in the above cell lines. Using transwell, each cell line was added
to the top chamber and its migration towards OPN was evaluated.
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Figure 3 CD44v6 and avb3 are highly expressed in granulocyte and monocyte but not lymphocyte subpopulation of hPBMCs. A
Representative side scatter vs. forward scatter plot of hPBMCs representing populations of lymphocytes (L), granulocytes (G) and monocytes (M).
B&C Expression of OPN receptors (avb3 (B) and CD44v6 (D)) was measured in hPBMCs and was evaluated in L vs. GM subsets. D Transwell
migration assay in L vs. GM subset indicated that only the latter is capable of migrating toward OPN thus providing a functional relevance of
expression of receptors.
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G12D-LSLp53
fl/fl GEMMs and implanting them sub-
cutaneously (without any in vitro manipulation) in
immunodeficient scid mice to create KPT (Kras
G12D-
LSLp53
fl/fl Trocar) mice. All the implanted tumors were
capable of growth and proliferation in the immunodefi-
cient recipients (Figure 4A). ELISA data showed elevated
levels of OPN in plasma in KPT mice suggesting a role
for OPN in tumor progression in this model (Figure
4B). FACS data indicated that both tumor cells and
PBMCs isolated from animals bearing these tumors
express avb3 and CD44 receptors further supporting a
rationale for treatment of sc-tumors with AOM1 (Figure
4C). Analysis of sc tumor volumes did not reveal any
s i g n i f i c a n td i f f e r e n c ea tt h ep r i m a r ys i t eo ft u m o r
growth in any of the treatment groups (including
AOM1 as single agent or in combination with Carbopla-
tin) suggesting that OPN may not play an important
role in tumor growth at the primary site of tumorigen-
esis (Figure 4D).
Lung metastasis is induced by OPN in KPT mice
In addition to primary tumor growth, the sc-implanted
tumors had the capacity to metastasize to the lung indi-
cating that tumor pieces from the GEMMs have main-
tained their invasive capacity. We analyzed metastasis in
the lungs and further classified tumor lesions as small,
medium, and large according to the size of the lesions
(Figure 5A). Pathology analysis indicated that while
there was no significant difference in the number of
small or medium tumors in the lung, AOM1 as single
agent or in combination with Carboplatin significantly
inhibited growth of large tumors (Figure 5B). In addition
analysis of the frequency of lung metastases showed a
significant decrease in the percentage of mice carrying
large lung tumors following treatment with AOM1 as
compared to the vehicle-treated animals, particularly in
combination treatment group (AOM1 plus Carboplatin)
where none of the mice carried large tumors as judged
by the histological analysis (Figure 5C). These observa-
tions suggest a role for OPN as a mediator of metastasis
in a preclinical model of NSCLC.
Discussion
Among molecular mediators of tumor growth and pro-
gression, OPN represents a complex target/pathway par-
ticularly in drug development. OPN has been identified
in several pathological tissues (inflammatory, obese, and
cancerous) in the organism [1]. OPN expression is ele-
vated during inflammation to recruit macrophages and
other immune infiltrating cells. A recent report shows
that OPN may play a significant role in obesity through
regulation of insulin signaling in liver cells and inflam-
mation [43]. In cancer, OPN is highly expressed in a
variety of tumors and appears to be a prognostic factor
correlating with tumor progression in patients. Despite
wide expression and involvement in multiple pathologi-
cal conditions, the lack of OPN in mice is not embryo-
nically lethal nor does it causes a prominent phenotype
c o m p a r e dt ow i l dt y p em i c es u g g e s t i n gt h a ta l t e r n a t i v e
mechanisms compensate for the lack of OPN or it may
not play a key role in embryonic development [44]. One
of the main challenges in characterizing role of OPN in
tumor progression is the existence of two distinct
families of receptors including integrins and CD44v6
that have the capacity to trigger downstream signaling
pathways independent of each other. Therefore, inhibi-
tion of one of the two receptors/pathways may not com-
pletely suppress OPN signalling and development of
therapeutic compounds to inhibit both receptors is
extremely challenging if not impossible.
In the tumor mass, OPN is secreted by both stroma
and cancer cells [36]. It appears that there are distinct
functions for tumor-derived vs. stromal-derived OPN in
tumor growth and metastasis. Crawford et al developed
a model of cutaneous squamous cell carcinoma in OPN
n u l lm i c ea n ds h o w e dt h a tw h i l et h en u m b e ro fm e t a -
static tumors is increased in this model, the size of
metastasized tumors was significantly lower compared
to corresponding wild typem i c e[ 4 5 ] .I ti ss u g g e s t e d
that stromal OPN may recruit anti-tumor macrophages
resulting in smaller tumor growth [45]. However, other
reports in melanoma [46] and breast [47] tumors sug-
gest that host-derived OPN is important r for tumor
growth and metastasis adding to the complexity of OPN
in tumor biology.
Here, we developed an anti-OPN antibody capable of
neutralizing human and mouse OPN, and utilized it to
investigate the role of OPN in preclinical models with
particular focus on lung cancer since a significant
amount of data supports a role for OPN in NSCLCs
[48]. All three transcripts of OPN have been identified
in NSCLC patients and gain-of-function analyses indi-
cate that OPNa, but not OPNb or OPNc, is involved in
increased proliferation, migration, and invasion of tumor
c e l l s[ 4 9 ] .S e r u mO P Nh a sb e e ns h o w nt oa c ta sab i o -
marker in lung carcinoma [38,50]. Conversely, reduction
in serum OPN (e.g. due to resection of primary tumors)
[51] is an indicator of better outcome in NSCLC
patients treated with cytotoxic agent [52]. Despite all
these reports, it remains to be clearly determined if
OPN is a biomarker and/or a driver of tumor progres-
sion in NSCLC.
The Kras
G12D-LSLp53
fl/fl mice [53] is one of the most
relevant preclinical models of NSCLC since 20-30% of
NSCLC patients carry Kras mutation [54] and 35-60%
show genetic aberrations in p53 [55]. Capacity of tumor
fragments to engraft in immuno-deficient animals pro-
vided an opportunity to test efficacy of AOM1 in
Shojaei et al. Journal of Experimental & Clinical Cancer Research 2012, 31:26
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Figure 4 Characterizing OPN and its receptors in mouse NSCLCs. A Development of KPT model. Kras
G12D-LSLp53
fl/fl (KP) mice were inhaled
with Adeno-CMV-Cre at approximately 8 weeks after birth. Lung tumors were inspected at approximately 18 weeks post-inhalation. Pieces of
lung tumors were taken from transgenic mice and were implanted subcutaneously (without any in vitro manipulation) into Scid/beige mice
using trocar to generate KPT (Kras
G12D-LSLp53
fl/fl trocar) model as described in the Materials and Methods. B Tumor implantation results in
increased levels of OPN in the plasma in tumor bearing mice. C Using flowcytometry, expression of CD44v6 and avb3 was evaluated in KP cells
and mPBMCs. Cells were stained with the antibodies as described in materials and methods and data analysis showed greater expression of
avb3 than CD44 in both KP and mPBMCs. D KPT mice were randomized and received treatments (Vehicle, AOM1, Carboplatin and combination)
at 8 days post-implantation. Tumors volume were measured twice/week and study was terminated at 27 days after implantation.
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Figure 5 AOM1 inhibits growth of large tumors in the lung in a NSCLC tumor. A Scid/beige mice were sc implanted with pieces of tumors
isolated from lung lesions from Kras
G12D-LSLp53
fl/fl mice. Implanted mice were randomized at 8 days post-implantation and were treated with
vehicle, AOM1, carboplatin and combination of both compounds. Tumor volume was measured using caliper twice per week. At terminal
analysis whole lung from each mouse was fixed in formalin and was stained in H&E. Representative images from each treatment are shown. In
pathology analysis lung lesions were classified into small (less than 10 cells) medium (10-200) and large (more than 200 cells) size and were
quantified in each treatment. B Quantifications of lesions in each treatment. Bar graph represents mean number of lesions ± SEM. C Frequency
of mice carrying each lesion in each treatment also indicated that AOM1 as single agent or in combination with Carboplatin significantly inhibits
percentage of mice carrying large tumors in the lung.
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Page 10 of 12NSCLC tumors. Lack of response to AOM1 in primary
tumor growth indicates an overlapping mechanism
between OPN and the other tumor-promoting factors.
However, inhibition of the growth of metastatic lesions,
which had been seeded prior to the initiation of AOM1
treatment, suggests a role for OPN as a mediator of
metastasis rather than a regulator of primary tumor
growth. Further investigation is needed to unravel
details of the role of OPN in lung metastasis. For exam-
ple, it remains to be determined if OPN promotes seed-
ing of a specific clone of tumor cells that will eventually
outgrow to large tumors in the lung or it is required to
further promote tumor growth at late stage in the meta-
static niche. Alternatively and given our in vitro data,
OPN may inhibit migration and seeding of clone of
tumor cells that may eventually rise to large tumors.
Future work in this direction will likely result in an
increased understanding of this complex protein that
might have some benefits for cancer patients
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